• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login
Home » All News » Vanrx’s Robotic Machines for Drug Industry Catch Eye of U.S. Med Giant

All News

  • Member News
  • Industry News
  • LSBC in The News
Member News

Vanrx’s Robotic Machines for Drug Industry Catch Eye of U.S. Med Giant

February 10, 2021
Cytiva

Chris Procyshyn kept hearing a common refrain when he began talking to potential customers about the robotic machines his B.C. company was developing.
“‘It sounds too good to be true,’” recalled the CEO of Vanrx Pharmasystems Inc., who co-founded the Burnaby-based company in 2007.

The machines — capable of safely filling liquid drugs into vials, syringes and cartridges – have since gained enough industry confidence to attract attention from more than a few medical giants.

And this month Vanrx became the first-ever acquisition completed by Cytiva since Danaher Corp.’s (NYSE:DHR) take-over of GE Life Sciences last year in a US$21.4-billion deal.

GE Life Sciences subsequently rebranded as Cytiva.

PwC facilitated the Cytiva-Vanrx deal. Terms of the deal were not disclosed. Read the full article by Tyler Orton here, on Business in Vancouver.

Contact:

Email: torton@biv.com

Twitter: @reporton

Primary Sidebar

  • Category:

  • Sector:

  • Archives:

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us